Glycosylation spectral signatures for glioma grade discrimination using Raman spectroscopy

2023 | journal article. A publication with affiliation to the University of Göttingen.

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Glycosylation spectral signatures for glioma grade discrimination using Raman spectroscopy​
Quesnel, A.; Coles, N.; Angione, C.; Dey, P.; Polvikoski, T. M.; Outeiro, T. F. & Islam, M. et al.​ (2023) 
BMC Cancer23(1).​ DOI: https://doi.org/10.1186/s12885-023-10588-w 

Documents & Media

document.pdf2.08 MBAdobe PDF

License

GRO License GRO License

Details

Authors
Quesnel, Agathe; Coles, Nathan; Angione, Claudio; Dey, Priyanka; Polvikoski, Tuomo M.; Outeiro, Tiago F.; Islam, Meez; Khundakar, Ahmad A.; Filippou, Panagiota S.
Abstract
Abstract Background Gliomas are the most common brain tumours with the high-grade glioblastoma representing the most aggressive and lethal form. Currently, there is a lack of specific glioma biomarkers that would aid tumour subtyping and minimally invasive early diagnosis. Aberrant glycosylation is an important post-translational modification in cancer and is implicated in glioma progression. Raman spectroscopy (RS), a vibrational spectroscopic label-free technique, has already shown promise in cancer diagnostics. Methods RS was combined with machine learning to discriminate glioma grades. Raman spectral signatures of glycosylation patterns were used in serum samples and fixed tissue biopsy samples, as well as in single cells and spheroids. Results Glioma grades in fixed tissue patient samples and serum were discriminated with high accuracy. Discrimination between higher malignant glioma grades (III and IV) was achieved with high accuracy in tissue, serum, and cellular models using single cells and spheroids. Biomolecular changes were assigned to alterations in glycosylation corroborated by analysing glycan standards and other changes such as carotenoid antioxidant content. Conclusion RS combined with machine learning could pave the way for more objective and less invasive grading of glioma patients, serving as a useful tool to facilitate glioma diagnosis and delineate biomolecular glioma progression changes.
Issue Date
2023
Journal
BMC Cancer 
eISSN
1471-2407
Language
English

Reference

Citations


Social Media